key: cord-0843750-rsz7ch2a
authors: Gil Melgaço, Juliana; Azamor, Tamiris; Paula Dinis Ano Bom, Ana
title: Protective immunity after COVID-19 has been questioned: what can we do without SARS-CoV-2-IgG detection?
date: 2020-04-28
journal: Cell Immunol
DOI: 10.1016/j.cellimm.2020.104114
sha: 25f80daba7e2d8ed9bafdd8421aed2e8767bc589
doc_id: 843750
cord_uid: rsz7ch2a

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a severe acute respiratory syndrome that is called COVID-19. Clinical manifestations of COVID-19 include diarrhea, pneumonia, lymphopenia, exhausted lymphocytes, and pro-inflammatory cytokine production. Immunology is part of the process of clinical evolution, but there are some questions around immunity-based protection: (1) why some infected people have only mild symptoms of the disease or are asymptomatic; (2) why delayed and weak antibody responses are associated with severe outcomes; and (3) why positivity in molecular tests does not represent protective antibody IgG. Perhaps T cell responses may be the key to solving those questions. SARS-CoV-2-specific memory T cells persist in peripheral blood and may be capable of providing effective information about protective immunity. The T cells studies can be helpful in elucidating the pathways for development of vaccines, therapies, and diagnostics for COVID-19 and for filling these immunology knowledge gaps.

100 Surprisingly, some a part of people who are presented ing positivity ion results from the

This situation raisesd questions about protective 104 immunity and about the time needed for quarantine. Given that, a few studies have already 105 showned that T cells might be the key to solvinge this dilemmaissue. Despite the finding 106 that the virus can induce lymphopenia and cause a the delay in T cells pathway activation 107 duringon the first days of infection, after two weeks of symptoms, SARS-CoV-2-specific 108 memory T cells phenotypes (central memory for CD4 and effector memory for CD8

This process is capable d and it is 110 able of to providinge useful effective information about protective immunity [6]. The data 111 that are needed to describe about how the memory phenotypes of T cells can differentiate 112 on a hasfollow-up study is not been elucidated yet. , and The minimal amount of few , but these studies are still ion the preclinical phase. Actually, we have seen a 117 change in the protective immunity status ofn viral diseases during vaccination

One of our hypotheses concerning around the novel coronavirus 123 suggest it has theis about its power to reduce B cell activity. and Tthis pathway should be 124 further explored. There is urgent need for solutions addressing around the time needed for 125 quarantine in order to prevent shutting the economy down. There to do not shut down the 126 economy may be have an answer to this problem in cellular response assays, in which the 127 cost is similar compared to neutralizing antibodies tests. Once we can evaluate a small 128 subpopulation that does not produce IgG antibodies, but in the meantime has activated T 129 cells after disease, ("in vitro" assays)

Adding to that, the cellular assays will provide information that is useful for for vaccine

Dysregulation of immune response in patients with COVID-19 in 142

COVID-19 infection: the perspectives on immune responses

A systematic review of 150 antibody mediated immunity to coronaviruses: antibody kinetics, correlates of 151 protection, and association of antibody responses with severity of disease

Neutralizing antibody responses to SARS-155

CoV-2 in a COVID-19 recovered patient cohort and their implications

Breadth 159 of concomitant immune responses underpinning viral clearance and patient recovery 160 in a non-severe case of COVID-19, Infectious Diseases (except HIV/AIDS)

Phenotype of SARS-CoV-2-165 specific T-cells in COVID-19 patients with acute respiratory distress syndrome, 166 Infectious Diseases (except HIV/AIDS)

Hepatitis B surface antigen-specific T and B cell memory in 169 individuals who had lost protective antibodies after hepatitis B vaccination, Vaccine

A single dose of inactivated 173 hepatitis A vaccine promotes HAV-specific memory cellular response similar to that 174 induced by a natural infection

Corrigendum to 177 "Human influenza viruses and CD8+ T cell responses

Memory T Cell Dynamics in the Lung during Influenza 181 Virus Infection